UK markets closed

SCYNEXIS, Inc. (0L49.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
1.4700+0.0350 (+2.44%)
At close: 06:28PM GMT
Full screen
Previous close1.4350
Open1.4700
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range1.4700 - 1.4700
52-week range1.3488 - 3.8550
Volume200
Avg. volume2,340
Market capN/A
Beta (5Y monthly)1.59
PE ratio (TTM)N/A
EPS (TTM)-1.2040
Earnings date08 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

    SCY-247’s IND-enabling activities continue to advance with initiation of Phase I anticipated in the second half of 2024 Data analysis for the FURI study is ongoing; top line data from the CARES study has been received and is positive and consistent with previously disclosed results from interim analyses The clinical study reports for FURI, CARES and NATURE in refractory invasive fungal infections are on target for delivery to GSK in the first half of 2024 which would trigger a $10 million develo

  • GlobeNewswire

    SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference

    JERSEY CITY, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced David Angulo, M.D., President and Chief Executive Officer, will present at Guggenheim’s 6th Annual Biotechnology Conference on Wednesday, February 7 at 11:00 A.M. ET. Guggenheim’s 6th Annual Biotechnology Conference Format: Fireside chat and one-on-one meetingsDate: Wed

  • GlobeNewswire

    SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

    In vivo data demonstrated response rate for oral SCY-247 similar to current standard of care, intravenous Liposomal Amphotericin B, for the treatment of mucormycosisCombination of SCY-247 and Liposomal Amphotericin B showed significant enhancement in survival and reduction in fungal burden in lung and brain tissue compared to monotherapies JERSEY CITY, N.J., Jan. 29, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and pr